As longevity science advances, researchers and advocates are exploring a familiar approach from cardiovascular medicine to help the public make sense of a rapidly growing field.

The science of healthy aging is moving quickly. Treatments targeting cellular aging, metabolic health and biological processes associated with aging are increasingly being studied in humans. Yet for the public, understanding what these developments actually mean, and which products or measurements can be trusted, can be difficult.

A recent perspective argues that the longevity community could learn from the way cardiovascular medicine communicates complex health information to the public.

From complex science to simple messages

Scientific fields typically have layers of expertise. At the center are researchers working at the frontiers of knowledge. Further out are clinicians, advocates, interested members of the public and, eventually, people with little specialized knowledge of the subject.

Information has to travel across these layers. As it moves outward, complicated scientific findings are simplified so they can be understood and used by people who do not have the time or training to study the research in depth.

That process is especially important in longevity science, where new technologies and commercial products are reaching consumers at a rapid pace.

A growing “implementation gap”

The field has made significant progress in areas such as senolytics, partial epigenetic reprogramming and GLP-1 metabolic therapies, with approaches entering human clinical trials.

At the same time, products aimed directly at consumers have expanded rapidly. These include biological-age tests, longevity clinics, biomarker panels and wearable devices that provide measurements such as readiness, recovery or aging scores.

The problem is that there is currently no universally accepted system for interpreting many of these measurements.

Two different companies, for example, may provide different estimates of a person’s “biological age,” while using different biomarkers or proprietary algorithms. Consumers may therefore find it difficult to understand what the numbers actually mean, or whether a change in the score reflects a meaningful improvement in health.

This disconnect between rapidly developing science and its practical use has been described as an “implementation gap.”

What cardiovascular medicine can teach longevity science

The perspective points to cardiovascular medicine’s Life’s Essential 8 as a possible model.

Life’s Essential 8 was developed to turn a complicated collection of cardiovascular risk factors into eight understandable components. Each component can be scored, producing an overall measure that is easier for the public to interpret than a large collection of individual medical measurements.

The approach illustrates how complicated scientific knowledge can be translated into a practical public-health message without requiring people to become experts in the underlying science.

Researchers studying aging face a similar challenge.

There is growing discussion among experts about which biomarkers should be used to evaluate interventions aimed at aging and age-related conditions